Interdisziplinäre S2-Therapieleitlinie der Juvenilen Idiopathischen Arthritis

N. Guellac; T. Niehues

doi:10.1055/s-0028-1086037

Klinische Pädiatrie, Inhaltsverzeichnis

Klin Padiatr 2008; 220(6): 392-402
DOI: 10.1055/s-0028-1086037

Mitteilungen

Interdisziplinäre S2-Therapieleitlinie der Juvenilen Idiopathischen Arthritis

Interdisciplinary and Evidence-based Treatment Guideline for Juvenile Idiopathic ArthritisN. Guellac¹ , T. Niehues^*

¹Zentrum für Kinder und Jugendmedizin, HELIOS Klinikum Krefeld
^*für die Konsensusgruppe (am Ende des Beitrags)

Abstract

Zusammenfassung

Die Therapie der Juvenilen Idiopathischen Arthritis (JIA) hat zu einer Verbesserung der Lebensqualität von Kindern und Jugendlichen geführt, variiert aber von Behandler zu Behandler noch erheblich. Eine Standardisierung der Therapie auf der Basis von Konsensusempfehlungen bietet die Chance, die Qualität der Versorgung von Kindern und Jugendlichen mit JIA weiter zu verbessern.

Ziel der Untersuchung: Evidenzbasierte S2- Leitlinie zum Thema JIA, basierend auf der bestehenden Leitlinie von 2005.

Methodik: Eine systematische Literaturanalyse wurde durchgeführt. Als Stichwörter wurden verwandt: juvenile idiopathic (rheumatoid) arthritis and therapy; als Suchbegrenzungen (Limits) in PUBMED: humans, published in the last 3 years, all child 0–18 years, clinical trial. Ausgeschlossen wurden Studien zur Diagnostik der JIA, Uveitis, Impfung, Transition und Rofecoxib. Die Autoren der GKJR-Leitlinie von 2005 und Vertreter aus folgenden Fachgesellschaften und Vereinigungen wurden zu professionell moderierten Konsensuskonferenzen eingeladen: Berufsverband der Kinder- und Jugendärzte (BVKJ), Deutsche Gesellschaft für Kinder- und Jugendmedizin (DGKJ), Deutsche Gesellschaft für Rheumatologie (DGRh), Deutsche Ophthalmologische Gesellschaft (DOG), Deutsche Rheuma-Liga Bundesverband, Verein zur Förderung und Unterstützung rheumatologisch erkrankter Kinder und deren Eltern, Vereinigung für Kinderorthopädie, Zentraler Verband der Physiotherapeuten und Krankengymnasten (ZVK). Die Konsensuskonferenzen am 9.5. und 1.8.2007 in Düsseldorf fanden unter >95% Teilnahme statt und die Konsensus-Statements wurden abschließend im Delphiverfahren abgestimmt.

Resultate und Zusammenfassung: Zu den Themen medikamentöse, symptomatische und chirurgische JIA-Therapie wurden Statements im Konsens erarbeitet und nach den Kriterien der evidenzbasierten Medizin bewertet.

Abstract

Treatment of Juvenile Idiopathic Arthritis (JIA) has improved quality of life in children and adolescents suffering from JIA. However, it varies considerably from caregiver to caregiver. Therefore a standardisation of care on the basis of consensus treatment recommendations offers the chance to further improve the quality of care for children and adolescents with JIA. We aimed to establish an interdisciplinary, evidence-based treatment guideline for JIA based on the existing guideline from 2005.

Methods: We did a systematic literature analysis in PUBMED with the key words “juvenile idiopathic (rheumatoid) arthritis” and “therapy”. As limits in PUBMED we used: humans, published in the last 3 years, all child 0–18 years, clinical trial. Studies relating to diagnosis of JIA, Uveitis, vaccination, transition and rofexocibe were excluded. Authors of the 2005 guideline and representatives nominated by different societies were invited to attend the consensus conferences which were hosted by a professional moderator. Following societies were invited: Berufsverband der Kinder- und Jugendärzte (BVKJ), Deutsche Gesellschaft für Kinder- und Jugendmedizin (DGKJ), Deutsche Gesellschaft für Rheumatologie (DGRh), Deutsche Ophthalmologische Gesellschaft (DOG), Deutsche Rheuma-Liga Bundesverband, Verein zur Förderung und Unterstützung rheumatologisch erkrankter Kinder und deren Eltern, Vereinigung für Kinderorthopädie, Zentraler Verband der Physiotherapeuten und Krankengymnasten (ZVK). Consensus conferences took place in Düsseldorf on May 9th and August 1st 2007 and were each attended by more than 95% of the nominated representatives Finally, statements were confirmed in a Delphi method.

Results and Conclusion: Consensus statements regarding drug therapy, symptomatic and surgical management of JIA were compiled and judged strictly by the criteria of Evidence-Based Medicine (EBM).

Schlüsselwörter

Juvenile Idiopathische Arthritis - evidenzbasierte Medizin - Therapieleitlinie - Kinder - Jugendliche - rheumatische Erkrankungen - Konsens

Key words

juvenile idiopathic arthritis - evidence-based medicine - treatment guideline - children - adolescence - consensus

Volltext

Referenzen

Literatur

1 Adebajo A, Hall M. The use of intravenous pulsed methylprednisolone in the treatment of systemic-onset juvenile chronic arthritis. Br J Rheumatol. 1998; 37 1240-1242
2 Andreae J. et al . Effect of glucocorticoid therapy on glucocorticoid receptors in children with autoimmune diseases. Pediatr Res. 2001; 49 130-135
3 April KT, Ehrmann Feldman ED, Platt RW. et al . Comparison between children with juvenile idiopathic arthritis (JIA) and their parents concerning perceived quality of life. Quality of Life Research. 2006; 15 655-661
4 Arabshahi B, Dewitt EM, Cahill AM. et al . Utility of corticosteroid injection for temporomandibular arthritis in children with juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52 ((11)) 3563-3569
5 Breit W. et al . A sub-group specific evaluation of the efficacy of intra-articular triamcinolone hexacetonide in juvenile chronic arthritis. J Rheumatol. 2000; 27 2696-2702
6 Brewer EJ, Giannini EH, Kuzmina N. et al . Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the USA – U.S.S.R. double-blind placebo-controlled trial. N Engl J Med. 1986; 314 1269-1276
7 Buttgereit F. et al . Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002; 61 718-722
8 Buttgereit F. Mechanisms and clinical relevance of nongenomic glucocorticoid actions. Z Rheumatol. 2000; 59 ((Suppl. 2)) 119-123
9 Cleary AG. et al . Intra-articular corticoid injections in juvenile idiopathic arthritis. Arch Dis Child. 2003; 88 192-196
10 Jong Z De, Munneke M, Zwinderman AH. et al . Is a long term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum. 2003; 48 ((9)) 2415-2424
11 Encke A, Kopp I, Selbmann HK. et al . Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), and Hrsg. Deutsches Instrument zur methodischen Bewertung von Leitlinien: DELBI. Dt Ärztebl. 2005; 102 (26) A1912-A1913 http://www.delbi.de , – Zugriff am 10.2.2008
12 Epps H, Ginnelly L, Utley M. et al . Is hydrotherapy cost-effective? A randomised controlled trial of combined hydrotherapy programmes compared with physiotherapy land techniques in children with juvenile idiopathic arthritis. Health Technol Assess. 2005; 9 ((39)) 1
13 Feldman BM, Grundland B, MacCullough L. et al . Distinction of quality of life, health related quality of life, and health status in children referred for rheumatologic care. J Rheumatol. 2000; 27 226-233
14 Feldmann W. Evidence-based Pediatrics. 1st ed. BC Decker, Hamilton 2000
15 Fink CW. Overview of corticoid therapy in the different rheumatic diseases of childhood. Clin Exp Rheumatol. 1991; 9 ((Suppl 6)) 9-13
16 Foeldvari I, Burgos-Vargas R, Thon A. et al . High response rate in the phase I/II study of meloxicam in juvenile rheumatoid arthritis. J Rheumatol. 2002; 29 ((5)) 1079-1083
17 Gao JS, Wu H, Tian J. Treatment of patients with juvenile rheumatoid arthritis with combination of leflunomide and methotrexate. Zhonghua Er Ke Za Zhi. 2003; 41 435-438
18 Giannini EH, Brewer EJ, Miller ML. et al . Ibuprofen suspension in the treatment f juvenile rheumatoid arthritis Pediatric Rheumatology Study Group. J Pediatr. 1990; 117 645-652
19 Haapasaari J, Wuolijoki E, Ylijoki H. Treatment of juvenile rheumatoid arthritis with diclofenac sodium. Scand J Rheumatol. 1983; 12 325-330
20 Hebestreit H, Müller-Scholden J, Huppertz HI. Aerobic Fitness and Physical Activity in Patients with HLA B27 Positive Juvenile Spondylarthropathy that is Inactive or in Remission. J Rheumatol. 1998; 25 1626-1633
21 Hoffmann JC, Fischer I, Höhne W. et al . Methodische Grundlagen für die Ableitung von Konsensusempfehlungen. Zeitschrift für Gastroenterologie. 2004; 42 ((9)) 84-87
22 Horneff G, Forster J, Seyberth HW. et al . Arbeitgemeinschaft Kinder- und Jugendrheumatologie. Recommendations by the Pediatric and Adolescent Rheumatology Study Committee on therapy with Etanercept (p75 TNF-alpha receptor immunoglobulin fusion protein. Pharmacotherapy Committee. Z Rheumatol. 2000; 59 ((6)) 365-369
23 Horneff G, Schmeling H, Biedermann T. et al . The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis. 2004; 1 1
24 Huppertz HI. et al . Intraarticular corticosteroids for chronic arthritis in children: efficacy and effects on cartilage and growth. J Pediatr. 1995; 127 317-321
25 Jones G, Bennell K, Cicuttini F M. Effect of physical activity on cartilage development in healthy kids. Br J Sports Med. 2003; 37 ((5)) 382-383
26 Kaiser H. Praxis der Cortisontherapie, ed. Kaiser, Urban und Schwarzenberg, München, 4. Auflage. 1996;
27 Katsicas MM, Russo RA. Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept. Clin Exp Rheumatol. 2005; 23 545-548
28 Kimura Y. et al . High dose, alternate day corticosteroids for systemic onset juvenile rheumatoid arthritis. J Rheumatol. 2000; 27 2018-2024
29 Klepper SE. Effects of an Eight-Week Physical Conditioning Program on Disease Signs and Symptoms in Children with Chronic Arthritis. Arthritis Care and Research. 1999; 12 52-60
30 Kvien TK, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol. 1986; 13 118-123
31 Kvien TK, Hoyeraal HM, Sandstad B. Naproxen and acetylsalicylic acid in the treatment of pauciarticular and polyarticular juvenile rheumatoid arthritis. Assessment of tolerance and efficacy in a single-centre 24-week double-blind parallel study. Scand J Rheumatol. 1984; 13 342-350
32 Langer HE. Patient education – a contribution to improvement of long-term management of patiets with rheumatism. Z Rheumatol. 1995; 54 207-212
33 Laxer RM, Silverman ED, St-Cyr C. et al . A six-month open safety assessment of a naproxen suspension formulation in the therapy of juvenile rheumatoid arthritis. Clin Ther. 1988; 10 381-387
34 Leak AM, Richter MR, Clemens LE. et al . A crossover study of naproxen, diclofenac and tolmetin in seronegative juvenile chronic arthritis. Clin Exp Rheumatol. 1988; 6 157-160
35 Lequerré T. et al . Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008; 67 ((3)) 302-308 , Epub 2007 Oct 18
36 Lovell DJ, Reiff A, Jones OY. et al . Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2006; 1987-1994
37 Malleson P, Bennett SM, Mac Kinnon M. et al . Physical Fitness and its Relationship to other Indices of Health Status in Children with Chronic Arthritis. J Rheumatol. 1996; 23 1059-1065
38 Manschwetus H. Quality standards and certification of patient education in rheumatology. Z Rheumatol. 2003; 62 II21-II23
39 Michels H. What is low dose corticosteroid therapy in juvenile idiopathic arthritis? A worldwide questionnaire-based survey. Z Rheumatol. 2000; 59 ((Suppl. 2)) 127-130
40 Müller-Godeffroy E, Lehmann H, Küster. et al . Lebensqualität und psychosoziale Anpassung bei Kindern und Jugendlichen mit juveniler idiopathischer Arthritis und reaktiven Arthritiden. Zeitschrift für Rheumatologie. 2005; 64 177-187
41 Niehues T, Horneff G, Michels H. et al . Evidence-based use of methotrexate in children with rheumatic disorders. Consensus statement of the Working Group for Children and Adolescents with Rheumatic Diseases in Germany (AGKJR) and the Working Group. Pediatric Rheumatology Austria Z Rheumatol. 2004; 63 ((2)) 147-158
42 Padeh S, Passwell JH. Intraarticular corticosteroid injection in the management of children with chronic arthritis. Arthritis Rheum. 1998; 41 1210-1214
43 Pistoia V, Buoncompagni A, Scribanis R. Cyclosporin A in the treatment of juvenile chronic arthritis and childhood polymyositis-dermatomyositis Results of a preliminary study. Clin Exp Rheumatol. 1993; 11 203-208
44 Powell M, Seid M, Szer IS. Efficacy of custom foot orthotics in improving pain and functional status in children with juvenile idiopathic arthritis: a randomized trial. J Rheum. 2005; 32 ((5)) 943-950
45 Prieur AM. The place of corticosteroid therapy in juvenile chronic arthritis in 1992. J Rheumatol. 1993; 37 32-34
46 Rasnake LK, Mervis K, Belpedio K. et al . Child and parent perceptions of child health-related quality of life in rheumatic disease: discrepancies and congruencies for ill and well dyads. Pediatric Rheumatology Online Journal. 2003; 1 187
47 Reiff A, Rawlings DJ, Shaham B. et al . Preliminary evidence for cyclosporin A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol. 1997; 24 2436-2443
48 Riddle R, Ryser CN, Morton AA. et al . The impact on health-related quality of life from non-steroidal anti-inflammatory drugs, methotrexate, or steroids in treatment for juvenile idiopathic arthritis. J Pediatr Psychol. 2006; 31 ((3)) 262-271 , Epub 2005 May 4
49 Ruperto N. et al . A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum. 2007; 56 ((9)) 3096-3106
50 Ruperto N, Kuzmina N, Pachanov E. et al . A randomized trial oftwo dose regimen of meloxicam compared to naproxen oral suspension in juvenile idiopathic arthritis. Arthritis Rheum. 2003; 48 ((9 (Suppl.)) S90-S91
51 Ruperto N, Murray KJ, Gerloni V. et al . A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004; 50 2191-2201
52 Sanden S. et al . Glucocorticoid dose dependent downregulation of glucocorticoid receptors in patients with rheumatic diseases. J Rheumatol. 2000; 27 1265-1270
53 Schaller JG. Corticosteroids in juvenile rheumatoid arthritis. Arthritis Rheum. 1977; 20 ((Suppl 2)) 537-543
54 Selbmann HK, Kopp I. Implementierung von Leitlinien in den Versorgungsalltag. Die Psychiatrie. 2005; 1 ((2)) 33-38
55 Silverman E, Mouy R, Spiegel L. et al . Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med. 2005; 352 1655-1666
56 Simon D. et al . Linear growth in children suffering from juvenile idiopatic arthritis requiring steroid therapy: natural history and effect of growth hormone treatment on linear growth. J Pediatr Endocrinol Metab. 2001; 14 ((Suppl 6)) 1483-1486
57 Singh-Grewal D, Wright V, Bar-Or O. et al . Pilot study of fitness training and exercise testing in polyarticular childhood arthritis. Arthritis Rheum. 2006; 55 364-372
58 Singh-Grewal D. The effects of vigorous exercise training on physical function in children with arthritis: a randomized, controlled, single-blinded trial. Arthritis Rheum. 2007; 57 ((7)) 1202-1210
59 Stoeber E, Sänger L. Erfahrungen mit Indometazin in der Langzeittherapie der juvenilen rheumatoiden Arthritis. Arzneimittelforschung. 1971; 21 ((11)) 1865-1866
60 Stritter FT, Tresolini CP, Reeb KG. The Delphi Technique in Curriculum Development. Teaching and Learning in Medicine. 1994; 6 ((2)) 136-141
61 Takken T, Der Net J Van, Kuis W. et al . Aquatic fitness training for children with juvenile idiopathic arthritis. Rheumatology (Oxford). 2003; 1408-1414
62 Takken T, Net J Van der, Kuis W. et al . Physical activity and health related physical fitness in children withjuvenileidiopathicarthritis. Ann Rheum Dis. 2003; 62 ((9)) 885-889
63 Toledo MM, Martini G, Gigante C. et al . Is there a role for arthroscopic synovectomy in oligoarticular juvenile idiopathic arthritis?. J Rheumatol. 2006; 33 1868-1872
64 Rossum MA van, Fiselier TJ, Franssen MJ. et al . Sulfasalazine in the treatment of juvenile chronic arthritis: a randomized, double-blind, placebo-controlled, multicenter study Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum. 1998; 41 808-816
65 Rossum MA van, Fiselier TJ, Franssen MJ. et al . Long-term outcome of Juvenile Idiopathic Arthritis following a placebo controlled trial: sustained benefits of early sulfasalazin treatment. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum Dis. 2007; 66 1518-1524
66 Schnakenburg K von. et al .Leitlinien Kinder- und Jugendmedizin. Rheumatologie Abschnitt H1: 1–15, Elsevier, 11. Lieferung 2005
67 Wagner N. Juvenile idiopathische Arthritis – Medikamentöse Therapie. In Bassler/Forster/Antes Evidenz basierte Pädiatrie, 1, Auflage. Thieme Verlag 2001
68 Yokota S. et al . Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371 ((9617)) 998-1006
69 Zulian F. et al . Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritis. Rheumatology. 2003; 42 1254-1259
70 Zulian F, Martini G, Gobber D. et al . Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trial. Rheumatology (Oxford). 2004; 43 ((10)) 1288-1291 , Epub 2004 Jul 13

Korrespondenzadresse

Prof. Dr. Tim Niehues

Zentrum für Kinder- und Jugendmedizin

HELIOS Klinikum Krefeld

Lutherplatz 40

47805 Krefeld

Telefon: +49/2151/32 23 01

Fax: +49/2151/32 23 34

eMail: tim.niehues@helios-kliniken.de